Company / Current Assets
Regeneron Pharmaceuticals Current Assets History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Assets
$18.0B
FY2025
5-year range
$14.0B / $19.5B
FY2021-FY2025
Trend
-3.4%
vs FY2024
Sector context
#9 of 213
Health Care
What the data says
Among 213 Health Care companies, Regeneron Pharmaceuticals is in the top 4% for current assets. Declined from $19.5B to $18.0B over the past 2 years.
Based on SEC 10-K filings.
$18.0B in FY2025 with a 5-year CAGR of +13.0%. Top quartile in the Health Care sector.
Declined from $19.5B to $18.0B over the past 2 years.
Health Care sector context is included.
Current Assets over time
Growth rates
- 3-Year CAGR
- +4.3%
- 5-Year CAGR
- +13.0%
- 10-Year CAGR
- -
Sector benchmark
Top 4% in Health CareTop 4% of 213This company $18.0B Sector average $2.5B
▼
+614.4% above sector average
Key checks
Key Insights
- 5-year CAGR of +13.0%, indicating consistent growth.
- In FY2025, current assets decreased 3.4% year-over-year.
- Ranks #9 out of 213 companies in the Health Care sector.
- Peak current assets was recorded in FY2023.
Company context
Key Data Points
- Altman Z-Score 3.03 (safe zone, above 2.9 threshold)
- Strong profit margin: 32.1%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current AssetsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $18.0B | -3.4% |
| FY2024 | $18.7B | -4.2% |
| FY2023 | $19.5B | +22.6% |
| FY2022 | $15.9B | +13.3% |
| FY2021 | $14.0B | +43.3% |
| FY2020 | $9.8B | +27.2% |
| FY2019 | $7.7B | +19.3% |
| FY2018 | $6.4B | +48.7% |
| FY2017 | $4.3B | +36.3% |
| FY2016 | $3.2B | +9.1% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026